Updated on 2024/11/13

Information

 

写真a

 
YAGI HIROSHI
 
Organization
Kyushu University Hospital Gynecology & Obstetrics Lecturer
School of Medicine Department of Medicine(Concurrent)
Title
Lecturer
External link

Degree

  • MD

Research History

  • なし

    なし

  • なし

Research Interests・Research Keywords

  • Research theme:The role of G13 signaling in the progression of gynecological cancer

    Keyword:GPCR、G13、cancer、metastasis

    Research period: 2017.4 - 2019.3

  • Research theme:The role of GPCR signaling in the progression of gynecological cancers

    Keyword:metastasis, GPCR

    Research period: 2014.4 - 2015.5

  • Research theme:The role of GPCR signaling in metastasis of gynecologic cancer

    Keyword:GPCR, cancer , metastasis

    Research period: 2012.9

Papers

  • Tumor-derived ARHGAP35 mutations enhance the Gα13-Rho signaling axis in human endometrial cancer. Reviewed International journal

    30 ( 2 )   313   2023.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/s41417-022-00547-1.

  • Gα13-mediated LATS1 down-regulation contributes to epithelial-mesenchymal transition in ovarian cancer Reviewed International journal

    2019.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • GEP oncogene promotes cell proliferation through YAP activation in ovarian cancer Reviewed International journal

    Yagi H, Asanoma K, Ohgami T, Ichinoe A, Sonoda K, Kato K

    ONCOGENE   35 ( 34 )   4471 - 4480   2016.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/onc.2015.505

  • A Synthetic Biology Approach Reveals a CXCR4-G(13)-RhoSignaling Axis Driving Transendothelial Migration of Metastatic Breast Cancer Cells Reviewed International journal

    Yagi H, Tan W, Dillenburg-Pilla P, Armando S, Amornphimoltham P, Simaan M, Weigert R, Molinolo AA, Bouvier M, Gutkind JS

    SCIENCE SIGNALING   4 ( 191 )   2011.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1126/scisignal.2002221

  • Clinical Significance of Tumor Immune Microenvironment in Endometrial Endometrioid Carcinoma, Grade 1 With DNA Mismatch Repair Protein Loss

    Hachisuga, K; Kawakami, M; Tomonobe, H; Maenohara, S; Kodama, K; Yagi, H; Yasunaga, M; Onoyama, I; Asanoma, K; Yahata, H; Oda, Y; Kato, K

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY   43 ( 6 )   573 - 585   2024.11   ISSN:0277-1691 eISSN:1538-7151

  • Endometrial senescence is mediated by interleukin 17 receptor B signaling (vol 22, 363, 2024)

    Kawamura, K; Matsumura, Y; Kawamura, T; Araki, H; Hamada, N; Kuramoto, K; Yagi, H; Onoyama, I; Asanoma, K; Kato, K

    CELL COMMUNICATION AND SIGNALING   22 ( 1 )   370   2024.7   eISSN:1478-811X

     More details

    Language:English   Publisher:Cell Communication and Signaling  

    Correction: Cell Commun Signal 22, 363 (2024). https://doi.org/10.1186/s12964-024-01740-5. Following publication of the original article [1], the authors reported that the incorrect additional file 12 was published. The correct additional file is published in this correction article and the original article [1] has been corrected.

    DOI: 10.1186/s12964-024-01754-z

    Web of Science

    Scopus

    PubMed

  • Endometrial senescence is mediated by interleukin 17 receptor B signaling

    Kawamura, K; Matsumura, Y; Kawamura, T; Araki, H; Hamada, N; Kuramoto, K; Yagi, H; Onoyama, I; Asanoma, K; Kato, K

    CELL COMMUNICATION AND SIGNALING   22 ( 1 )   363   2024.7   eISSN:1478-811X

     More details

    Language:English   Publisher:Cell Communication and Signaling  

    Background: We previously identified Il17RB, a member of the IL17 superfamily, as a candidate marker gene for endometrial aging. While IL17RB has been linked to inflammation and malignancies in several organ systems, its function in the endometrium has not been investigated and is thus poorly understood. In the present study, we performed a functional analysis of this receptor with the aim of determining the effects of its age-associated overexpression on the uterine environment. Methods: We analyzed IL17RB-related signaling pathways and downstream gene expression in an immortalized human endometrial glandular epithelial cell line (“hEM”) forced to express the receptor via lentiviral transduction (“IL17RB-hEM”). We also prepared endometrial organoids from human endometrial tissue sourced from hysterectomy patients (“patient-derived EOs”) and exposed them to cytokines that are upregulated by IL17RB expression to investigate changes in organoid-forming capacity and senescence markers. We analyzed RNA-seq data (GEO accession number GSE132886) from our previous study to identify the signaling pathways associated with altered IL17RB expression. We also analyzed the effects of the JNK pathway on organoid-forming capacity. Results: Stimulation with interleukin 17B enhanced the NF-κB pathway in IL17RB-hEM, resulting in significantly elevated expression of the genes encoding the senescence associated secretory phenotype (SASP) factors IL6, IL8, and IL1β. Of these cytokines, IL1β inhibited endometrial organoid growth. Bioinformatics analysis showed that the JNK signaling pathway was associated with age-related variation in IL17RB expression. When IL17RB-positive cells were cultured in the presence of IL17B, their organoid-forming capacity was slightly but non-significantly lower than in unexposed IL17RB-positive cells, but when IL17B was paired with a JNK inhibitor (SP600125), it was restored to control levels. Further, IL1β exposure significantly reduced organoid-forming capacity and increased p21 expression in endometrial organoids relative to non-exposure (control), but when IL1β was paired with SP600125, both indicators were restored to levels comparable to the control condition. Conclusions: We have revealed an association between IL17RB, whose expression increases in the endometrial glandular epithelium with advancing age, and cellular senescence. Using human endometrial organoids as in vitro model, we found that IL1β inhibits cell proliferation and leads to endometrial senescence via the JNK pathway.

    DOI: 10.1186/s12964-024-01740-5

    Web of Science

    Scopus

    PubMed

  • 術前補助化学療法後の巨大再発成人顆粒膜細胞腫に対して完全縮小手術を施行した1例(Complete reduction surgery of a huge recurrent adult granulosa cell tumor after neoadjuvant chemotherapy)

    Tokui Hiroha, Yahata Hideaki, Okabe Yasuhiro, Magarifuchi Naomi, Maenohara Shoji, Hachisuga Kazuhisa, Tomonobe Hiroshi, Kodama Keisuke, Yagi Hiroshi, Yasunaga Masafumi, Onoyama Ichiro, Asanoma Kazuo, Oda Yoshinao, Nakamura Masafumi, Kato Kiyoko

    International Cancer Conference Journal   13 ( 2 )   162 - 166   2024.4

     More details

    Language:English   Publisher:シュプリンガー・ジャパン(株)  

    症例は72歳女性、2妊2産であった。卵巣悪性腫瘍に対して52歳時に開腹子宮全摘術、両側卵管卵巣摘出術、大網切除術、骨盤リンパ節郭清術を施行され、最終診断はステージIaの成人型顆粒膜細胞腫(AGCT)であった。初回手術から19年後、他施設で受けたCTで後腹膜腫瘍が偶然発見された。腫瘍は直径11×10cmで、肝門部、下大静脈、右腎静脈が隆起していた。CTガイド下腫瘍生検によりAGCTの再発が確認された。腫瘍が巨大であり、完全切除を行うと出血多量による術中死亡のリスクがあると考えられた。そこで、パクリタキセル+カルボプラチン(PC)による術前化学療法を行い、再発腫瘍を縮小させた。その後、縮小手術を行った。再発腫瘍の完全切除に成功し、手術時間は12時間54分、出血量は700gであった。切除標本の病理所見からAGCTの再発と診断した。術後1年経過時点で再発は認められなかった。

  • Complete reduction surgery of a huge recurrent adult granulosa cell tumor after neoadjuvant chemotherapy

    Tokui, H; Yahata, H; Okabe, Y; Magarifuchi, N; Maenohara, S; Hachisuga, K; Tomonobe, H; Kodama, K; Yagi, H; Yasunaga, M; Onoyama, I; Asanoma, K; Oda, Y; Nakamura, M; Kato, K

    INTERNATIONAL CANCER CONFERENCE JOURNAL   13 ( 2 )   162 - 166   2024.4   ISSN:2192-3183

     More details

  • The BHLHE40‒PPM1F‒AMPK pathway regulates energy metabolism and is associated with the aggressiveness of endometrial cancer Reviewed International journal

    Asanoma, K; Yagi, H; Onoyama, I; Cui, L; Hori, E; Kawakami, M; Maenohara, S; Hachisuga, K; Tomonobe, H; Kodama, K; Yasunaga, M; Ohgami, T; Okugawa, K; Yahata, H; Kitao, H; Kato, K

    JOURNAL OF BIOLOGICAL CHEMISTRY   300 ( 3 )   105695   2024.3   ISSN:00219258 eISSN:1083-351X

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Journal of Biological Chemistry  

    BHLHE40 is a basic helix-loop-helix transcription factor that is involved in multiple cell activities including differentiation, cell cycle, and epithelial-to-mesenchymal transition. While there is growing evidence to support the functions of BHLHE40 in energy metabolism, little is known about the mechanism. In this study, we found that BHLHE40 expression was downregulated in cases of endometrial cancer of higher grade and advanced disease. Knockdown of BHLHE40 in endometrial cancer cells resulted in suppressed oxygen consumption and enhanced extracellular acidification. Suppressed pyruvate dehydrogenase (PDH) activity and enhanced lactated dehydrogenase (LDH) activity were observed in the knockdown cells. Knockdown of BHLHE40 also led to dephosphorylation of AMPKα Thr172 and enhanced phosphorylation of pyruvate dehydrogenase E1 subunit alpha 1 (PDHA1) Ser293 and lactate dehydrogenase A (LDHA) Tyr10. These results suggested that BHLHE40 modulates PDH and LDH activity by regulating the phosphorylation status of PDHA1 and LDHA. We found that BHLHE40 enhanced AMPKα phosphorylation by directly suppressing the transcription of an AMPKα-specific phosphatase, PPM1F. Our immunohistochemical study showed that the expression of BHLHE40, PPM1F, and phosphorylated AMPKα correlated with the prognosis of endometrial cancer patients. Because AMPK is a central regulator of energy metabolism in cancer cells, targeting the BHLHE40‒PPM1F‒AMPK axis may represent a strategy to control cancer development.

    DOI: 10.1016/j.jbc.2024.105695

    Web of Science

    Scopus

    PubMed

  • Clinical Significance of Tumor Immune Microenvironment in Endometrial Endometrioid Carcinoma, Grade 1 With DNA Mismatch Repair Protein Loss. Reviewed International journal

    Hachisuga K, Kawakami M, Tomonobe H, Maenohara S, Kodama K, Yagi H, Yasunaga M, Onoyama I, Asanoma K, Yahata H, Oda Y, Kato K.

    Int J Gynecol Pathol   2024.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1097/PGP.0000000000001020.

  • Development of novel tracers for sentinel node identification in cervical cancer

    Kodama Keisuke, Tateishi Chuya, Oda Tsuyoshi, Cui Lin, Kuramoto Kazutaka, Yahata Hideaki, Okugawa Kaoru, Maenohara Shoji, Yagi Hiroshi, Yasunaga Masafumi, Onoyama Ichiro, Asanoma Kazuo, Mori Takeshi, Katayama Yoshiki, Kato Kiyoko

    Cancer Science   114 ( 11 )   4216 - 4224   2023.11   ISSN:13479032 eISSN:13497006

     More details

    Language:English  

    Indocyanine green (ICG) with near-infrared (NIR) fluorescence imaging is used for lymphatic mapping. However, binding of ICG to blood proteins like serum albumin can shorten its retention time in sentinel lymph nodes (SLNs). Here, we investigated the efficacy and safety of a new fluorescence tracer comprising phytate and liposome (LP)-encapsulated ICG. Coadministration of phytate with LP containing phosphatidic acid promotes chelation mediated by Ca^<2+> in bodily fluids to enhance SLN retention. Uniformly sized LPs (100 nm) encapsulating ICG under conditions that minimized fluorescence self-quenching during storage were produced. We analyzed the behavior of the new tracer (ICG-phytate-LP) and control tracers (ICG and ICG-LP) in the lymphatic flow of mice in terms of lymph node retention time. We also tested lymphatic flow and safety in pigs that have a more human-like lymphatic system. LPs encapsulating stabilized ICG were successfully prepared. Mixing LP with phytate in the presence of Ca^<2+> increased both the particle size and negative surface charge. In mice, ICG-phytate-LP had the best lymph node retention, with a fluorescence intensity ratio that increased over 6 h and then decreased slowly over the next 24 h. In pigs, administration of ICG and ICG-phytate-LP resulted in no death or weight loss. There were no obvious differences between blood test results for the ICG and ICG-phytate-LP groups, and the overall safety was good. ICG-phytate-LP may be a useful new tracer for gynecological cancers that require time for lymph node identification due to a retroperitoneal approach.

    CiNii Research

  • Development of novel tracers for sentinel node identification in cervical cancer. Reviewed International journal

    Kodama K, Tateishi C, Oda T, Cui L, Kuramoto K, Yahata H, Okugawa K, Maenohara S, Yagi H, Yasunaga M, Onoyama I, Asanoma K, Mori T, Katayama Y, Kato K.

    Cancer Sci   114 ( 11 )   4216   2023.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/cas.15927.

  • 子宮頸癌例でのセンチネルリンパ節同定に用いる新規トレーサーの開発(Development of novel tracers for sentinel node identification in cervical cancer)

    Kodama Keisuke, Tateishi Chuya, Oda Tsuyoshi, Cui Lin, Kuramoto Kazutaka, Yahata Hideaki, Okugawa Kaoru, Maenohara Shoji, Yagi Hiroshi, Yasunaga Masafumi, Onoyama Ichiro, Asanoma Kazuo, Mori Takeshi, Katayama Yoshiki, Kato Kiyoko

    Cancer Science   114 ( 11 )   4216 - 4224   2023.11   ISSN:1347-9032

     More details

    Language:English   Publisher:John Wiley & Sons Australia, Ltd  

    センチネルリンパ節(SLN)を同定するためのトレーサーとして、リポソーム封入インドシアニングリーン(ICG)とフィチン酸塩で構成される新規な蛍光トレーサーを開発し、その有効性と安全性を調査した。まず、安定化したICGが封入されているリポソームを調製した。次にキレート反応が発揮されることを期待し、Ca2+の存在下でリポソームとフィチン酸塩を混和した。その結果、生成される粒子のサイズとその表面の陰電荷が共に増加した。このようにICG、リポソーム、フィチン酸塩を構成要素とした新規トレーサーがマウスのリンパ節内に滞留する時間を評価した。その結果、対照のトレーサー(ICGおよびリポソーム封入ICG)と比較して最も良好な滞留性を発揮した。その蛍光強度比は6時間かけて上昇し、次いで24時間かけて緩やかに低下していった。ブタで安全性評価を行ったが、本新規トレーサーを投与しても死亡または体重減少は発生しなかった。ICGのみ投与した場合との明確な違いも示されず、全安全性は良好であった。本新規トレーサーは、後腹膜アプローチのためリンパ節を同定する時間が必要になる婦人科癌で有用なものになると考えられた。

  • Development of novel tracers for sentinel node identification in cervical cancer

    Kodama, K; Tateishi, C; Oda, T; Cui, L; Kuramoto, K; Yahata, H; Okugawa, K; Maenohara, S; Yagi, H; Yasunaga, M; Onoyama, I; Asanoma, K; Mori, T; Katayama, Y; Kato, K

    CANCER SCIENCE   114 ( 11 )   4216 - 4224   2023.11   ISSN:1347-9032 eISSN:1349-7006

     More details

    Language:English   Publisher:Cancer Science  

    Indocyanine green (ICG) with near-infrared (NIR) fluorescence imaging is used for lymphatic mapping. However, binding of ICG to blood proteins like serum albumin can shorten its retention time in sentinel lymph nodes (SLNs). Here, we investigated the efficacy and safety of a new fluorescence tracer comprising phytate and liposome (LP)-encapsulated ICG. Coadministration of phytate with LP containing phosphatidic acid promotes chelation mediated by Ca2+ in bodily fluids to enhance SLN retention. Uniformly sized LPs (100 nm) encapsulating ICG under conditions that minimized fluorescence self-quenching during storage were produced. We analyzed the behavior of the new tracer (ICG-phytate-LP) and control tracers (ICG and ICG-LP) in the lymphatic flow of mice in terms of lymph node retention time. We also tested lymphatic flow and safety in pigs that have a more human-like lymphatic system. LPs encapsulating stabilized ICG were successfully prepared. Mixing LP with phytate in the presence of Ca2+ increased both the particle size and negative surface charge. In mice, ICG-phytate-LP had the best lymph node retention, with a fluorescence intensity ratio that increased over 6 h and then decreased slowly over the next 24 h. In pigs, administration of ICG and ICG-phytate-LP resulted in no death or weight loss. There were no obvious differences between blood test results for the ICG and ICG-phytate-LP groups, and the overall safety was good. ICG-phytate-LP may be a useful new tracer for gynecological cancers that require time for lymph node identification due to a retroperitoneal approach.

    DOI: 10.1111/cas.15927

    Web of Science

    Scopus

    PubMed

  • Decision-making for Subsequent Therapy for Patients With Recurrent or Advanced Endometrial Cancer Based on the Platinum-free Interval. Reviewed International journal

    Kodama K, Tateishi C, Oda T, Cui L, Kuramoto K, Yahata H, Okugawa K, Maenohara S, Yagi H, Yasunaga M, Onoyama I, Asanoma K, Mori T, Katayama Y, Kato K.

    Am J Clin Oncol.   46 ( 9 )   387   2023.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1097/COC.0000000000001021.

  • Decision-making for Subsequent Therapy for Patients With Recurrent or Advanced Endometrial Cancer Based on the Platinum-free Interval

    Yasunaga, M; Yahata, H; Okugawa, K; Hori, E; Hachisuga, K; Maenohara, S; Kodama, K; Yagi, H; Ohgami, T; Onoyama, I; Asanoma, K; Kato, K

    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS   46 ( 9 )   387 - 391   2023.9   ISSN:0277-3732 eISSN:1537-453X

     More details

    Language:English   Publisher:American Journal of Clinical Oncology: Cancer Clinical Trials  

    Objective: The aim of this study was to evaluate the progression-free survival (PFS) and overall response rate (ORR) of patients with recurrent endometrial cancer (REC) or advanced endometrial cancer (AEC) retreated with platinum-containing chemotherapy (PCC) based on the platinum-free interval (PFI). We compared our results with those reported in the KEYNOTE-775 study (that used pembrolizumab plus lenvatinib). Methods: A retrospective analysis was conducted of 65 patients with REC or AEC retreated with PCC between 2005 and 2020 at our hospital. Various clinicopathologic variables were analyzed: (1) age, (2) performance status, (3) histology, (4) history of pelvic irradiation in the adjuvant setting, (5) PFI, (6) chemotherapy regimen, (7) PFS and overall survival after retreatment with PCC, and (8) best ORR. Survival analyses were performed using Kaplan-Meier curves and log-rank tests. Results: The best ORR and PFS were 43.3% and 9.5 months, respectively, in patients with REC/AEC with a PFI ≥6 months. These results were comparable with those of patients treated with pembrolizumab and lenvatinib. The best ORR and PFS of patients with a PFI of <6 months appeared to be inferior to those of patients treated with pembrolizumab plus lenvatinib. Conclusions: Pembrolizumab plus lenvatinib seems to be a better treatment choice for patients with REC or AEC with a PFI of <6 months. For a PFI of ≥6 months, pembrolizumab plus lenvatinib or PCC can be used depending on the degree of residual side -effects associated with cytotoxic agents.

    DOI: 10.1097/COC.0000000000001021

    Web of Science

    Scopus

    PubMed

  • Secondary Adrenal Insufficiency Due to Isolated ACTH Deficiency Induced by Pembrolizumab: A Report of Two Cases of Uterine Endometrial Cancer

    Onoyama, I; Kawakami, M; Hachisuga, K; Maenohara, S; Kodama, K; Yagi, H; Yasunaga, M; Ohgami, T; Asanoma, K; Yahata, H; Kitamura, Y; Sakamoto, R; Kiyozawa, D; Kato, K

    REPORTS   6 ( 2 )   2023.6   eISSN:2571-841X

  • Tumor-derived ARHGAP35 mutations enhance the Gα<sub>13</sub>-Rho signaling axis in human endometrial cancer

    Yagi, H; Onoyama, I; Asanoma, K; Kawakami, M; Maenohara, S; Kodama, K; Matsumura, Y; Hamada, N; Hori, E; Hachisuga, K; Yasunaga, M; Ohgami, T; Okugawa, K; Yahata, H; Kato, K

    CANCER GENE THERAPY   30 ( 2 )   313 - 323   2023.2   ISSN:0929-1903 eISSN:1476-5500

     More details

    Language:English   Publisher:Cancer Gene Therapy  

    Dysregulated G protein-coupled receptor signaling is involved in the formation and progression of human cancers. The heterotrimeric G protein Gα13 is highly expressed in various cancers and regulates diverse cancer-related transcriptional networks and cellular functions by activating Rho. Herein, we demonstrate that increased expression of Gα13 promotes cell proliferation through activation of Rho and the transcription factor AP-1 in human endometrial cancer. Of interest, the RhoGTPase activating protein (RhoGAP), ARHGAP35 is frequently mutated in human endometrial cancers. Among the 509 endometrial cancer samples in The Cancer Genome Atlas database, 108 harbor 152 mutations at 126 different positions within ARHGAP35, representing a somatic mutation frequency of 20.2%. We evaluated the effect of 124 tumor-derived ARHGAP35 mutations on Gα13-mediated Rho and AP-1 activation. The RhoGAP activity of ARHGAP35 was impaired by 55 of 124 tumor-derived mutations, comprised of 23 nonsense, 15 frame-shift, 15 missense mutations, and two in-frame deletions. Considering that ARHGAP35 is mutated in >2% of all tumors, it ranks among the top 30 most significantly mutated genes in human cancer. Our data suggest potential roles of ARHGAP35 as an oncogenic driver gene, providing novel therapeutic opportunities for endometrial cancer.

    DOI: 10.1038/s41417-022-00547-1

    Web of Science

    Scopus

    PubMed

  • Tumor-derived ARHGAP35 mutations enhance the Ga13-Rho signalling axis in human endometrial cancer

    Yagi, H; Kawakami, M; Maenohara, S; Kodama, K; Matsumura, Y; Onoyama, I; Asanoma, K; Kato, K

    CANCER SCIENCE   114   1863 - 1863   2023.2   ISSN:1347-9032 eISSN:1349-7006

     More details

  • Epigenetic characterization of ovarian serous carcinoma with lymph-node metastasis by 5-hydroxymethylcytosine sequencing

    Onoyama, I; Kato, M; Kawakami, M; Maenohara, S; Kodama, K; Yagi, H; Asanoma, K; Kato, K

    CANCER SCIENCE   114   918 - 918   2023.2   ISSN:1347-9032 eISSN:1349-7006

     More details

  • 子宮体癌再発を疑った大網放線菌症の1例

    清武 早紀, 安永 昌史, 蜂須賀 一寿, 安武 伸子, 前之原 章司, 八木 裕史, 大神 達寛, 小野山 一郎, 奥川 馨, 淺野間 和夫, 矢幡 秀昭, 加藤 聖子

    福岡産科婦人科学会雑誌   46 ( 2 )   18 - 22   2023.1   ISSN:2187-7211

     More details

    Language:Japanese   Publisher:福岡産科婦人科学会  

    症例は76歳、3妊3産。不正性器出血を主訴に前医を受診し、子宮内膜肥厚を認め、精査加療目的に当科を紹介受診した。当科の子宮内膜全面掻爬にて子宮内膜異型増殖症の診断で、全腹腔鏡下単純子宮全摘出術+両側付属器摘出術を施行した。最終診断は子宮体癌IA期、類内膜癌G1の診断で、再発低リスク群であり、追加治療は施行せず経過観察とした。2年後の造影CT検査で大網左側に結節状の軟部陰影と周囲脂肪織混濁を認め再発が疑われた。CTガイド下生検を施行し、病理組織検査で非特異的な炎症所見を認めるのみで、悪性所見は認めなかった。更に1年後のCTで軟部陰影は増大傾向であり、子宮体癌再発の可能性も否定できず、診断確定目的に大網部分切除術を施行した。最終病理組織診断の結果は放線菌症の診断であった。放線菌症は悪性腫瘍との鑑別が難しいため、非典型的な臨床経過の場合は放線菌感染も鑑別の一つとして念頭においておくべきと思われた。(著者抄録)

  • Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer. Reviewed International journal

    Yasunaga M, Yahata H, Okugawa K, Shimokawa M, Maeda Y, Hori E, Kodama K, Yagi H, Ohgami T, Onoyama I, Asanoma K, Kato K.

    Taiwan J Obstet Gynecol.   61 ( 5 )   818   2022.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.tjog.2022.06.005.

  • Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer

    Yasunaga, M; Yahata, H; Okugawa, K; Shimokawa, M; Maeda, Y; Hori, E; Kodama, K; Yagi, H; Ohgami, T; Onoyama, I; Asanoma, K; Kato, K

    TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY   61 ( 5 )   818 - 822   2022.9   ISSN:1028-4559

     More details

    Language:English   Publisher:Taiwanese Journal of Obstetrics and Gynecology  

    Objective: Recent randomized phase III trial has shown significant benefit in overall survival (OS) for patients with advanced cervical cancer by adding bevacizumab to conventional chemotherapy. The aim of this study was to evaluate the prognostic impact for Japanese recurrent, persistent, or metastatic cervical cancer patients where bevacizumab was added to paclitaxel plus carboplatin. Materials and methods: A retrospective analysis was performed on 90 patients with recurrent, persistent, or metastatic cervical cancer mainly treated by paclitaxel plus carboplatin between 2005 and 2019 at our hospital. Data for the following clinicopathological variables were analyzed: (1) bevacizumab use; (2) histology; (3) disease presentation; (4) performance status; (5) prior chemotherapy containing platinum agent; (6) pelvic disease; (7) prior pelvic radiotherapy; (8) location of target lesions. Survival analysis was performed using Kaplan–Meier curves, log-rank tests, Wilcoxon tests, and Cox proportional hazards models combined with propensity score matching. Results: Adding bevacizumab to paclitaxel plus carboplatin showed significantly increased complete response to compared with that of non-users. In a Cox regression hazard model, bevacizumab use tended to show better OS though without statistically significance. After propensity score matching, adding bevacizumab to paclitaxel plus carboplatin showed a significant better OS by univariate analysis using Wilcoxon test, not by log-rank test. Conclusion: Adding bevacizumab to paclitaxel plus carboplatin showed a limited prognostic impact for recurrent, persistent or advanced cervical cancer patients in the real world. Further effective second-line treatments are needed to prolong OS of patients with recurrent, persistent or advanced cervical cancer.

    DOI: 10.1016/j.tjog.2022.06.005

    Web of Science

    Scopus

    PubMed

  • 再発子宮頸癌に対するペムブロリズマブ療法中に内腸骨動脈-S状結腸瘻を生じた一例(Arterio-enteric fistula in a patient with recurrent cervical cancer treated with pembrolizumab)

    永谷 優華, 八木 裕史, 久保 雄一郎, 牛島 泰宏, 堀 絵美子, 川上 穣, 友延 寛, 安武 伸子, 吉田 祥子, 小玉 敬亮, 安永 昌史, 大神 達寛, 小野山 一郎, 奥川 馨, 淺野間 和夫, 谷口 秀一, 嶋本 富博, 矢幡 秀昭, 石神 康生, 加藤 聖子

    宮崎県医師会医学会誌   46 ( 2 )   147 - 153   2022.9   ISSN:0389-8288

     More details

    Language:English   Publisher:(公社)宮崎県医師会  

    動脈-腸管瘻は消化管出血の原因としてはまれであるが,初発症状が致死性の大量出血の場合もある緊急性の高い疾患である。症例は44歳,9妊7産,子宮頸癌IB3期(扁平上皮癌)に対して広汎子宮全摘出術,両側付属器摘出術,術後補助療法として同時化学放射線療法を施行した。治療終了6ヵ月後に骨盤内再発を認め,全身化学療法を施行したが奏効しなかった。MSI検査の結果,MSI-highであったためペムブロリズマブ療法を開始した。腫瘍の著明な縮小を認め,4コース後の治療効果判定はPRであった。ペムブロリズマブ療法4コース目day7,当科入院中に突然,多量の下血,意識レベルの低下を認めた。緊急造影CTの結果,左内腸骨動脈からS状結腸への造影剤の漏出を認め,左内腸骨動脈-S状結腸瘻と診断した。直ちに左内腸骨動脈塞栓術を施行し止血した。発症から止血まで3時間の間に赤血球32単位,新鮮凍結血漿28単位,血小板10単位の輸血を要した。(著者抄録)

  • Long-term follow up after sentinel node biopsy alone for early-stage cervical cancer. Reviewed International journal

    Yahata H, Kodama K, Okugawa K, Hachisuga K, Yasutake N, Maenohara S, Yagi H, Yasunaga M, Ohgami T, Onoyama I, Asanoma K, Kobayashi H, Sonoda K, Baba S, Ishigami K, Ohishi Y, Oda Y, Kato K.

    Gynecol Oncol   165 ( 1 )   149   2022.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.ygyno.2022.01.031.

  • Long-term follow up after sentinel node biopsy alone for early-stage cervical cancer

    Yahata, H; Kodama, K; Okugawa, K; Hachisuga, K; Yasutake, N; Maenohara, S; Yagi, H; Yasunaga, M; Ohgami, T; Onoyama, I; Asanoma, K; Kobayashi, H; Sonoda, K; Baba, S; Ishigami, K; Ohishi, Y; Oda, Y; Kato, K

    GYNECOLOGIC ONCOLOGY   165 ( 1 )   149 - 154   2022.4   ISSN:0090-8258 eISSN:1095-6859

     More details

    Language:English   Publisher:Gynecologic Oncology  

    Objective: Sentinel node biopsy alone (SNB) reduces the postoperative complications of pelvic lymphadenectomy, such as lymphedema and lymphangitis; however, the long-term prognosis after SNB is unclear. The objective of this study was to evaluate the long-term outcome and complications of patients with early-stage cervical cancer who underwent SNB for hysterectomy or trachelectomy. Methods: We performed SNB for cervical cancer using a radioisotope method in 181 patients between 2009 and 2017. If the intraoperative sentinel lymph node evaluation was negative for metastasis, no further lymph nodes were removed. Results: The median age of the patients was 34 years (range, 21–73 years). The International Federation of Gynecology and Obstetrics 2008 stage was IA1 in 6 patients, IA2 in 18, IB1 in 154, and IIA1 in 3. Of the 181 patients (44 with hysterectomy, 137 with trachelectomy), 8 did not undergo pelvic lymphadenectomy because of a false-negative intraoperative diagnosis, 20 received adjuvant therapy after surgery, and 4 (2.2%) experienced recurrence over a median follow-up period of 83.5 months (range, 25–145 months). In the four recurrent cases, recurrence occurred in the pelvis, lung, and bone in one patient each, while the remaining patient developed pelvic and para-aortic lymph node metastases. Of these four patients, one died, and the remaining three are alive without disease after multidisciplinary therapy. The 5-year progression-free and overall survival rates were 98.8% and 99.4%, respectively. Postoperative complications, such as lymphedema, were very low rate. Conclusions: SNB for early-stage cervical cancer might be safe and effective, with no increase in the recurrence and postoperative complications rate.

    DOI: 10.1016/j.ygyno.2022.01.031

    Web of Science

    Scopus

    PubMed

  • Evaluation of Clinical Significance of Lymphovascular Space Invasion in Stage IA Endometrial Cancer

    Okugawa, K; Yahata, H; Hachisuga, K; Tomonobe, H; Yasutake, N; Kodama, K; Kenjo, H; Yagi, H; Ohgami, T; Yasunaga, M; Onoyama, I; Asanoma, K; Hori, E; Ohishi, Y; Oda, Y; Kato, K

    ONCOLOGY   100 ( 4 )   195 - 202   2022.4   ISSN:0030-2414 eISSN:1423-0232

     More details

    Language:English   Publisher:Oncology (Switzerland)  

    Introduction: The prognostic significance of lymphovascular space invasion (LVSI) in stage IA endometrial cancer remains unclear. The aim of this study was to evaluate the clinical significance of LVSI in stage IA endometrial cancer. Methods: Clinical data of patients with stage IA endometrial cancer who underwent initial surgery at our institution between January 2008 and December 2018 were reviewed retrospectively. Information of patients, surgery, and characteristics of cancer were obtained from medical records and pathological reports. Results: Two hundred ninety-seven patients were enrolled in this study. With a median follow-up of 60 months, 15 patients experienced recurrence (5.1%) and 4 patients died of endometrial cancer (1.3%). The recurrence and mortality rates did not differ significantly between the LVSI-positive and-negative groups (p = 0.07 and p = 0.41, respectively). Recurrence-free survival and endometrial cancer-specific survival also did not differ significantly between these groups (p = 0.11 and p = 0.49, respectively). The 5-year endometrial cancer-specific survival rates for tumors with and without LVSI were 97.0% and 98.9%, respectively. Among patients with low-grade tumors, recurrence-free survival and endometrial cancer-specific survival did not differ significantly between patients with tumors with and without LVSI (p = 0.92 and p = 0.72, respectively). The 5-year endometrial cancer-specific survival rates for low-grade tumors with and without LVSI were 100% and 99.3%, respectively. Conclusion: LVSI was not a prognostic factor of not only stage IA endometrial cancer but also stage IA low-grade cancer.

    DOI: 10.1159/000521382

    Web of Science

    Scopus

    PubMed

  • Tumor-derived mutations in ARHGAP35 promote Gα<sub>13</sub>-induced AP1 activation in human endometrial cancer cells

    Yagi, H; Kodama, K; Matsumura, Y; Onoyama, I; Asanoma, K; Kato, K

    CANCER SCIENCE   113   1539 - 1539   2022.2   ISSN:1347-9032 eISSN:1349-7006

     More details

  • Downregulation of 5-hydroxymethylcytosine is associated with the progression of cervical intraepithelial neoplasia

    Onoyama, I; Kato, M; Kawakami, M; Kodama, K; Yagi, H; Asanoma, K; Kato, K

    CANCER SCIENCE   113   727 - 727   2022.2   ISSN:1347-9032 eISSN:1349-7006

     More details

  • Evaluation of Clinical Significance of Lymphovascular Space Invasion in Stage IA Endometrial Cancer. Reviewed International journal

    Okugawa K, Yahata H, Hachisuga K, Tomonobe H, Yasutake N, Kodama K, Kenjo H, Yagi H, Ohgami T, Yasunaga M, Onoyama I, Asanoma K, Hori E, Ohishi Y, Oda Y, Kato K

    Oncology   100 ( 4 )   195   2021.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1159/000521382.

  • Prognostic impact of the subclassification of Müllerian cancer stage IV in the FIGO 2014 staging system with a focus of extra-abdominal lymph node metastases. Reviewed International journal

    26 ( 7 )   1330   2021.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s10147-021-01908-w.

  • Prognostic outcomes and risk factors for recurrence after laser vaporization for cervical intraepithelial neoplasia: a single-center retrospective study. Reviewed International journal

    Kodama K, Yahata H, Okugawa K, Tomonobe H, Yasutake N, Yoshida S, Yagi H, Yasunaga M, Ohgami T, Onoyama I, Asanoma K, Hori E, Shimokawa M, Kato K.

    Int J Clin Oncol.   26 ( 4 )   770   2021.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s10147-020-01848-x.

  • Hypersensitivity reaction to pegylated liposomal doxorubicin administration for Mullerian carcinoma in Japanese women. Reviewed International journal

    Yamaguchi S, Yahata H, Okugawa K, Kodama K, Yagi H, Yasunaga M, Ohgami T, Onoyama I, Asanoma K, Kato K.

    J Obstet Gynaecol Res.   47 ( 4 )   1544   2021.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/jog.14680.

  • Identification of genes associated with endometrial cell ageing. Reviewed International journal

    Kawamura T, Tomari H, Onoyama I, Araki H, Yasunaga M, Lin C, Kawamura K, Yokota N, Yoshida S, Yagi H, Asanoma K, Sonoda K, Egashira K, Ito T, Kato K.

    Mol Hum Reprod   27 ( 2 )   2021.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1093/molehr/gaaa078.

  • YBX2 and cancer testis antigen 45 contribute to stemness, chemoresistance and a high degree of malignancy in human endometrial cancer. Reviewed International journal

    Suzuki I, Yoshida S, Tabu K, Kusunoki S, Matsumura Y, Izumi H, Asanoma K, Yagi H, Onoyama I, Sonoda K, Kohno K, Taga T, Itakura A, Takeda S, Kato K.

    Sci Rep   11 ( 1 )   4220   2021.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/s41598-021-83200-5.

  • Fibronectin mediates activation of stromal fibroblasts by SPARC in endometrial cancer cells Reviewed International journal

    Yoshida S, Asanoma K, Yagi H, Onoyama I, Hori E, Matsumura Y, Okugawa K, Yahata H, Kato K

    BMC Cancer   21 ( 1 )   1 - 12   2021.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Evaluation of adjuvant chemotherapy after abdominal trachelectomy for cervical cancer: a single-institution experience. Reviewed International journal

    Okugawa K, Yahata H, Sonoda K, Kodama K, Yagi H, Ohgami T, Yasunaga M, Onoyama I, Kaneki E, Asanoma K, Kobayashi H, Kato K.

    Int J Clin Oncol.   26 ( 1 )   216   2021.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s10147-020-01778-8.

  • Downregulation of 5-hydroxymethylcytosine is associated with the progression of cervical intraepithelial neoplasia. Reviewed International journal

    Kato M, Onoyama I, Kawakami M, Yoshida S, Kawamura K, Kodama K, Hori E, Cui L, Matsumura Y, Yagi H, Asanoma K, Yahata H, Itakura A, Takeda S, Kato K.

    PLoS One   15 ( 11 )   2020.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1371/journal.pone.0241482.

  • Dual-specificity phosphatase 6 plays a critical role in the maintenance of a cancer stem-like cell phenotype in human endometrial cancer. Reviewed International journal

    Kato M, Onoyama I, Yoshida S, Cui L, Kawamura K, Kodama K, Hori E, Matsumura Y, Yagi H, Asanoma K, Yahata H, Itakura A, Takeda S, Kato K.

    Int J Cancer   147 ( 7 )   1987   2020.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/ijc.32965.

  • Is Adjuvant Therapy Necessary for Patients with Intermediate-Risk Cervical Cancer after Open Radical Hysterectomy? Reviewed International journal

    17. Yahata H, Sonoda K, Inoue S, Yasutake N, Kodama K, Yagi H, Yasunaga M, Ohgami T, Onoyama I, Kaneki E, Okugawa K, Asanoma K, Kato K.

    Oncology.   98 ( 12 )   853   2020.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1159/000508569.

  • Retrospective analysis of treatment and prognosis for uterine leiomyosarcoma: 10-year experience of a single institute. Reviewed International journal

    Kodama K, Sonoda K, Kijima M, Yamaguchi S, Yagi H, Yasunaga M, Ohgami T, Onoyama I, Kaneki E, Okugawa K, Yahata H, Ohishi Y, Oda Y, Kato K.

    Asia Pac J Clin Oncol   16 ( 2 )   2019.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/ajco.13286.

  • Survey of the desire to have children and engage in sexual activity after trachelectomy among young Japanese women with early-stage cervical cancer. Reviewed International journal

    Yahata H, Sonoda K, Okugawa K, Yagi H, Ohgami T, Yasunaga M, Onoyama I, Kaneki E, Asanoma K, Kato K.

    45 ( 11 )   2255   2019.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/jog.14099.

  • Mutual suppression between BHLHE40/BHLHE41 and the MIR301B-MIR130B cluster is involved in epithelial-to-mesenchymal transition of endometrial cancer cells. Reviewed International journal

    Asanoma K, Hori E, Yoshida S, Yagi H, Onoyama I, Kodama K, Yasunaga M, Ohgami T, Kaneki E, Okugawa K, Yahata H, Kato K.

    Oncotarget   10 ( 45 )   4640   2019.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.18632/oncotarget.27061.

  • Amphiregulin regulates the production of human chorionic gonadotropin in trophoblasts Reviewed International journal

    Fukami T, Yoshizato T, Miyamoto S, Yagi H, Yotsumoto F, Nabeshima K, Hachisuga T, Kuroki M, Kawarabayashi T.

    84 ( 23-24 )   796   2019.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.lfs.2009.03.009.

  • Prognostic outcome and complications of sentinel lymph node navigation surgery for early-stage cervical cancer. Reviewed International journal

    Yahata H, Kobayashi H, Sonoda K, Kodama K, Yagi H, Yasunaga M, Ohgami T, Onoyama I, Kaneki E, Okugawa K, Baba S, Isoda T, Ohishi Y, Oda Y, Kato K.

    Int J Clin Oncol   23 ( 6 )   1167   2018.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s10147-018-1327-y.

  • Fibrosis in Preeclamptic Placentas Is Associated with Stromal Fibroblasts Activated by the Transforming Growth Factor-β1 Signaling Pathway. Reviewed International journal

    188 ( 3 )   683   2018.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.ajpath.2017.11.008.

  • Serum Heparin-binding Epidermal Growth Factor-like Growth Factor (HB-EGF) as a Biomarker for Primary Ovarian Cancer Reviewed International journal

    Miyata K, Yotsumoto F, Fukagawa S, Kiyoshima C, Ouk NS, Urushiyama D, Ito T, Katsuda T, Kurakazu M, Araki R, Sanui A, Miyahara D, Murata M, Shirota K, Yagi H, Takono T, Kato K, Yaegashi N, Akazawa K, Kuroki M, Yasunaga S, Miyamoto S.

    37 ( 7 )   3955   2017.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.21873/anticanres.11779.

  • MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer Reviewed International journal

    Fukagawa S, Miyata K, Yotsumoto F, Kiyoshima C, Nam SO, Anan H, Katsuda T, Miyahara D, Murata M, Yagi H, Shirota K, Yasunaga S, Kato K, Miyamoto S.

    Cancer Sci   108 ( 5 )   886   2017.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/cas.13210.

  • FBXW7 is involved in the acquisition of the malignant phenotype in epithelial ovarian tumors. Reviewed International journal

    Kitade S, Onoyama I, Kobayashi H, Yagi H, Yoshida S, Kato M, Tsunematsu R, Asanoma K, Sonoda K, Wake N, Hata K, Nakayama KI, Kato K.

    Cancer Sci   107 ( 10 )   1399   2016.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/cas.13026.

  • Regulation of the Mechanism of TWIST1 Transcription by BHLHE40 and BHLHE41 in Cancer Cells Invited Reviewed International journal

    Asanoma K, Liu G, Yamane T, Miyanari Y, Takao T, Yagi H, Ohgami T, Ichinoe A, Sonoda K, Wake N, Kato K

    MOLECULAR AND CELLULAR BIOLOGY   35 ( 24 )   4096 - 4109   2015.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1128/MCB.00678-15

  • Identification of the Critical Site of Calponin 1 for Suppression of Ovarian Cancer Properties. Reviewed International journal

    Yamane T, Asanoma K, Kobayashi H, Liu G, Yagi H, Ohgami T, Ichinoe A, Sonoda K, Wake N, Kato K.

    Anticancer Res   35 ( 11 )   5993   2015.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Retrospective Analysis of Concurrent Chemoradiation with Triweekly Cisplatin plus 5-Fluorouracil Versus Weekly Cisplatin in Cervical Cancer. Reviewed International journal

    Sonoda K, Yahata H, Ichinoe A, Okugawa K, Kaneki E, Kawano Y, Kenjo H, Ohgami T, Yagi H, Ohga S, Asai K, Nakamura K, Honda H, Kato K.

    Anticancer Res   35 ( 6 )   3447   2015.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-specific expression of MDM2 in endometrial cancers Reviewed International journal

    Okamoto K, Tsunematsu R, Tahira T, Sonoda K, Asanoma K, Yagi H, Yoneda T, Hayashi K, Wake N, Kato K.

    BMC Med Genet   16 ( 67 )   2015.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1186/s12881-015-0216-8.

  • Pre-clinical study of BK-UM, a novel inhibitor of HB-EGF, for ovarian cancer therapy. Reviewed International journal

    Nam SO, Yotsumoto F, Miyata K, Suzaki Y, Yagi H, Odawara T, Manabe S, Ishikawa T, Kuroki M, Mekada E, Miyamoto S.

    Anticancer Res   34 ( 8 )   4615   2014.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • PDZ-RhoGEF and LARG are essential for embryonic development and provide a link between thrombin and LPA receptors and Rho activation. Reviewed International journal

    Mikelis CM, Palmby TR, Simaan M, Li W, Szabo R, Lyons R, Martin D, Yagi H, Fukuhara S, Chikumi H, Galisteo R, Mukouyama YS, Bugge TH, Gutkind JS.

    J Biol Chem   288 ( 17 )   12232   2013.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1074/jbc.M112.428599.

  • Clinical significance of amphiregulin and epidermal growth factor in colostrum Invited Reviewed International journal

    Nojiri T, Yoshizato T, Fukami T, Obama H, Yagi H, Yotsumoto F, Miyamoto S

    ARCHIVES OF GYNECOLOGY AND OBSTETRICS   286 ( 3 )   643 - 647   2012.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00404-012-2365-8

  • A novel anti-human HB-EGF monoclonal antibody with multiple antitumor mechanisms against ovarian cancer cells. International journal

    Miyamoto S, Iwamoto R, Furuya A, Takahashi K, Sasaki Y, Ando H, Yotsumoto F, Yoneda T, Hamaoka M, Yagi H, Murakami T, Hori S, Shitara K, Mekada E.

    Clin Cancer Res   17(21):6733-41 ( 21 )   2011.11

     More details

    Publishing type:Research paper (scientific journal)  

  • Identification of the Rac-GEF P-Rex1 as an Essential Mediator of ErbB Signaling in Breast Cancer Reviewed International journal

    Sosa MS, Lopez-Haber C, Yang C, Wang H, Lemmon MA, Busillo JM, Luo J, Benovic JL, Klein-Szanto A, Yagi H, Gutkind JS, Parsons RE, Kazanietz MG

    MOLECULAR CELL   40 ( 6 )   877 - 892   2010.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.molcel.2010.11.029

  • Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer. Reviewed International journal

    Yotsumoto F, Fukami T, Yagi H, Funakoshi A, Yoshizato T, Kuroki M, Miyamoto S.

    Cancer Sci   101 ( 11 )   2351   2010.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/j.1349-7006.2010.01671.x.

  • Semaphorin 3E Initiates Antiangiogenic Signaling through Plexin D1 by Regulating Arf6 and R-Ras Reviewed International journal

    Sakurai A, Gavard J, Annas-Linhares Y, Basile JR, Amornphimoltham P, Palmby TR, Yagi H, Zhang F, Randazzo PA, Li X, Weigert R, Gutkind JS

    MOLECULAR AND CELLULAR BIOLOGY   30 ( 12 )   3086 - 3098   2010.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1128/MCB.01652-09

  • Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer. Reviewed International journal

    Yagi H, Yotsumoto F, Sonoda K, Kuroki M, Mekada E, Miyamoto S

    Int J Cancer   124 ( 6 )   2009.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition. Reviewed International journal

    Yagi H, Yotsumoto F, Miyamoto S

    Int J Cancer   7 ( 10 )   3441   2008.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 0.1158/1535-7163.MCT-08-0417.

  • Validation of hb-egf and amphiregulin as targets for human cancer therapy. Reviewed International journal

    Yotsumoto F, Yagi H, Suzuki SO, Oki E, Tsujioka H, Hachisuga T, Sonoda K, Kawarabayashi T, Mekada E, Miyamoto S.

    Bioche Biophys Res Commun   365 ( 3 )   555   2008.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.bbrc.2007.11.015.

  • Clinical significance of RCAS1 as a biomarker of ovarian cancer. Reviewed International journal

    Sonoda K, Miyamoto S, Yotsumoto F, Yagi H, Nakashima M, Watanabe T, Nakano H.

    Oncol Rep   17 ( 3 )   623   2007.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Clinical significance of RCAS1 as a biomarker of uterine cancer. Reviewed International journal

    Sonoda K, Miyamoto S, Hirakawa T, Yagi H, Yotsumoto F, Nakashima M, Watanabe T, Nakano H

    Gynecol Oncol   103 ( 3 )   924   2006.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.ygyno.2006.05.047.

  • Invasive potency related to RCAS1 expression in uterine cervical cancer Reviewed International journal

    Sonoda K, Miyamoto S, Hirakawa T, Yagi H, Yotsumoto F, Nakashima M, Watanabe T, Nakano H

    Gynecol Oncol   99 ( 1 )   189   2005.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.ygyno.2005.06.061.

  • Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Reviewed International journal

    Tanaka Y, Miyamoto S, Suzuki SO, Oki E, Yagi H, Sonoda K, Yamazaki A, Mizushima H, Maehara Y, Mekada E, Nakano H.

    Clin Cancer Res   11 ( 13 )   4783   2005.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1158/1078-0432.CCR-04-1426.

  • Association between RCAS1 expression and microenvironmental immune cell death in uterine cervical cancer. Reviewed International journal

    Sonoda K, Miyamoto S, Hirakawa T, Yagi H, Yotsumoto F, Nakashima M, Watanabe T, Nakano H

    Gynecol Oncol   97 ( 3 )   772   2005.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.ygyno.2005.02.025.

  • Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer Reviewed International journal

    Yagi H, Miyamoto S, Tanaka Y, Sonoda K, Kobayashi H, Kishikawa T, Iwamoto R, Mekada E, Nakano H.

    Br J Cancer   92 ( 9 )   1737   2005.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/sj.bjc.6602536.

  • Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Reviewed International journal

    Miyamoto S, Hirata M, Yamazaki A, Kageyama T, Hasuwa H, Mizushima H, Tanaka Y, Yagi H, Sonoda K, Kai M, Kanoh H, Nakano H, Mekada E.

    Cancer Res   64 ( 16 )   5720   2004.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1158/0008-5472.CAN-04-0811.

▼display all

Books

  • The role of G protein-coupled receptor signaling in The role of G protein-coupled receptor signaling in gynecologic malignancy. Molecular Diagnosis and Targeting for Gynecologic Malignancy.

    Hiroshi Yagi and Kiyoko Kato( Role: Joint author)

    Springer  2021.3 

     More details

    Responsible for pages:p57-70   Language:English  

Presentations

▼display all

MISC

  • 新たな診断・治療開発に向けた婦人科がん分子機構の解明レビュー 三量体Gタンパクの機能解析に基づいた新たな婦人科がん治療の開発

    八木 裕史

    日本産科婦人科学会雑誌   74 ( 10 )   1596 - 1608   2022.10   ISSN:0300-9165

     More details

    Language:Japanese   Publisher:(公社)日本産科婦人科学会  

  • Potential for molecularly targeted therapy against epidermal growth factor receptor ligands Reviewed

    Miyamoto S, Fukami T, Yagi H, Kuroki M, Yotsumoto F

    Anticancer Res   2009.5

     More details

    Language:English   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)  

  • Heparin-binding epidermal growth factor-like growth factor as a new target molecule for cancer therapy Reviewed

    Miyamoto S, Yagi H, Yotsumoto F, Kawarabayashi T, Mekada E

    Adv Exp Med Biol   2008.6

     More details

    Language:English   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)  

    DOI: 10.1007/978-0-387-68969-2_23.

  • Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy Reviewed

    Miyamoto S, Yagi H, Yotsumoto F, Kawarabayashi T, Mekada E

    Cancer Sci   2007.11

     More details

    Language:English   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)  

  • New approach to cancer therapy: heparin binding-epidermal growth factor-like growth factor as a novel targeting molecule Reviewed

    Miyamoto S, Yagi H, Yotsumoto F, Horiuchi S, Yoshizato T, Kawarabayashi T, Kuroki M, Mekada E

    Anticancer Res   2007.11

     More details

    Language:English   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)  

  • HB-EGF is a promising target molecule for ovarian cancer

    Miyamoto S, Yagi H, Tanaka Y

    Fukuoka Igaku Zasshi   2004.11

     More details

    Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)  

▼display all

Professional Memberships

  • 日本癌学会

  • 日本婦人科腫瘍学会

  • 日本産科婦人科学会

  • 日本癌治療学会

Research Projects

  • 婦人科がんの発生および悪性形質獲得における三量体Gタンパクの役割

    Grant number:21K09496  2021 - 2023

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    八木 裕史

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding

    Gタンパク共役受容体(GPCR)を介したシグナル伝達経路は癌の進展に深く関与している。ヒト癌組織を用いた網羅的遺伝子解析の結果、GPCRやそのリガンドだけでなく、細胞内でcouplingする三量体Gタンパク、エフェクター分子、低分子量Gタンパクなど、そのシグナル伝達を制御する様々な分子の異常が重要な役割を果たしていることが明らかとなった。
    三量体Gタンパクの一つであるGα13は様々な癌の進展に関与していることが報告されているが、その詳細なメカニズムについては明らかになっていない。本研究では、Gα13が制御するシグナル伝達経路、癌の発生および悪性形質の獲得における役割を明らかにすることである。

    CiNii Research

  • 婦人科悪性腫瘍の進展におけるGa13の役割

    2018.6

      More details

    Authorship:Principal investigator 

  • 婦人科悪性腫瘍の進展におけるGα13の役割

    Grant number:17K11282  2017 - 2019

    日本学術振興会  科学研究費助成事業  基盤研究(C)

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding

  • 婦人科悪性腫瘍の転移を制御するGPCRシグナルの解析

    Grant number:26861332  2014 - 2015

    科学研究費助成事業  若手研究(B)

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding

  • 婦人科癌の転移におけるGPCRの役割

    2012.9

      More details

    Authorship:Principal investigator 

  • 婦人科悪性腫瘍の転移を制御するシグナル伝達経路の解析

    Grant number:24791709  2012 - 2014

    科学研究費助成事業  若手研究(B)

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding

▼display all

Award for Educational Activities

  • なし

       

Class subject

  • がん専門医師養成科目

    2023.4 - 2023.9   First semester

  • がん専門医師養成科目

    2022.4 - 2022.9   First semester

  • がん専門医師養成科目

    2021.4 - 2021.9   First semester

  • がん専門医師養成科目

    2019.4 - 2019.9   First semester

  • 保健学科、母体疾病論

    2018.4 - 2018.9   First semester

  • 保健学科、高次助産学演習

    2018.4 - 2018.9   First semester

  • がん専門医師養成科目

    2018.4 - 2018.9   First semester

  • 保健学科、母性疾病論

    2017.4 - 2017.9   First semester

  • 保健学科、高次助産学演習

    2017.4 - 2017.9   First semester

▼display all

Travel Abroad

  • 2007.10 - 2010.11

    Staying countory name 1:United States   Staying institution name 1:米国国立衛生研究所

Specialized clinical area

  • Biology / Medicine, Dentistry and Pharmacy / Surgical Clinical Medicine / Obstetrics and Gynecology

Clinician qualification

  • Specialist

    Japan Society of Obstetrics and Gynecology(JSOG)

  • Preceptor

    Japan Society of Obstetrics and Gynecology(JSOG)

Year of medical license acquisition

  • 2001